Qiagen, Vidac Pharma, and Bayer with groundbreaking news

Bayer – The end of the dry spell

The downward trend of the crisis-ridden pharmaceutical and agricultural giant seems to have been stopped for the time being. After hitting a low of EUR 18.40 in November last year, Bayer shares fought their way up to the horizontal resistance level of EUR 20.50. A break of this prominent line would provide a buy signal with a follow-up potential up to the zone of around EUR 25.

The price of the Leverkusen-based company received a boost from a report by its biotech subsidiary BlueRock, which announced a breakthrough in the development of a new method for combating Parkinson's. The cell therapy bemdaneprocel will soon begin a Phase 3 study relevant to approval, as the Leverkusen-based pharmaceutical and agricultural group Bayer announced. The study will follow on directly from the Phase 1 study and was planned in close consultation with the US Food and Drug Administration after evaluating the results. The study is scheduled to start in the first half of the year and will involve around 102 patients with moderate Parkinson's disease.

Bayer secured the treatment technology in 2019 through its acquisition of BlueRock. According to the companies, this is the first Phase 3 study worldwide for a Parkinson's therapy developed from allogeneic pluripotent stem cells. The aim of bemdaneprocel is to replace lost dopamine-producing nerve cells. These cells are derived from pluripotent stem cells that originally came from human embryonic stem cells and are then implanted in the patient's brain. There, they are intended to repair damaged neural networks and restore both motor and non-motor functions.

Vidac Pharma – Further milestones

Since the end of May of the past stock market year 2024, shares of the biopharmaceutical oncology company have risen by approximately 275% to EUR 0.74. According to the analyst firm Sphene Capital, the price target, which was already set around six months ago, is EUR 4.90, offering a further price potential of 562%.

It is worth noting that since the analysis, Vidac Pharma has achieved further milestones in its business development. For example, the US Patent and Trademark Office expanded the patent protection for the active ingredients of the oncology drug candidates VDA-1102 and CDA-1275. The expansion covers, among other things, metastases of prostate cancer, pancreatic cancer, as well as colon, cervical, and lung cancer.

The Company, led by Max Herzberg, one of the founders of the Israeli life sciences industry, was able to report further groundbreaking news at the end of the year with the receipt of the final report from the Helsinki Committee at Beilinson Hospital on its groundbreaking clinical study on cutaneous T-cell lymphoma (CTCL).

There is currently no standard treatment for the condition, which causes severe skin inflammation and lesions caused by cancerous T-cells in the blood and lymphatic system. The Company's innovative ointment VDA-1102 aims to block the hyperglycolysis typical of cancer cells while providing a targeted and effective treatment option.

The report, submitted to the Israeli Ministry of Health, highlights promising results and enables the Company to move on to a crucial Phase 2/3 study. A successful outcome of this phase would be a significant step towards product registration.

Qiagen – On to new all-time highs

The chart of the Hilden-based company, which develops solutions for sample preparation and analysis of biological materials, also looks promising. Qiagen's products and technologies are used in molecular diagnostics, research, and forensics to isolate, analyse and interpret DNA, RNA and proteins.

Since the interim low at EUR 33.75 in early November, Qiagen's stock chart has formed an ascending triangle. If the horizontal resistance at EUR 44.78 is broken to the upside, the next price target is at the all-time high at EUR 53.15. The stock is receiving tailwinds from the trend-following MACD indicator and the Relative Strength Index (RSI), both of which have issued "Buy" signals.

Qiagen also provided a "Buy" signal from a fundamental perspective by rewarding its shareholders through a synthetic share repurchase of up to EUR 300 million. This involves a capital measure combining a direct capital repayment with a reverse stock split. The process is to be completed by the end of January and includes the repayment of an amount corresponding to the planned volume at the beginning of 2024. At least USD 1 billion is expected to be returned to shareholders by the end of 2028.

According to Qiagen, the synthetic share repurchase will enable a faster and more efficient return of cash than traditional buyback programs. In addition, earnings per share will increase due to the reduction in the number of shares outstanding.

After a long dry spell, the pharmaceutical and agricultural giant Bayer's stock is on the verge of a strong buy signal. Qiagen's stock could start an attack on new all-time highs following a breakout from its horizontal resistance. Vidac Pharma is taking another step towards product registration with its oncology drug candidate VDA-1102.